Tafasitamab
- Generic Name
- Tafasitamab
- Brand Names
- Monjuvi, Minjuvi
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1422527-84-1
- Unique Ingredient Identifier
- QQA9MLH692
- Background
Tafasitamab is a humanized, CD19-directed cytolytic monoclonal antibody intended for the treatment of B-cell malignancies. It is produced using recombinant DNA technology in Chinese hamster ovary cells, and contains an IgG1/2 hybrid Fc-domain which has been modified with 2 amino acid substitutions to enhance its cytotoxicity relative to non-engineered anti-C...
- Indication
Tafasitamab is indicated, in combination with lenalidomide, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified whom are ineligible for autologous stem cell transplant (ASCT).
- Associated Conditions
- Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Relapsed Diffuse large B-cell lymphoma NOS
- Associated Therapies
- -
Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL
- Conditions
- Interventions
- First Posted Date
- 2019-10-22
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- MorphoSys AG
- Target Recruit Count
- 66
- Registration Number
- NCT04134936
- Locations
- 🇪🇸
MorphoSys Research Site, Vitoria-Gasteiz 1009, Spain
A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)
- Conditions
- Interventions
- First Posted Date
- 2019-04-29
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Celgene
- Target Recruit Count
- 438
- Registration Number
- NCT03930953
- Locations
- 🇨🇱
Pontificia Universidad Catolica de Chile-Hemato-Oncology, Santiago, Metropolitana, Chile
🇨🇳Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
🇺🇸Mayo Clinic Arizona - Scottsdale, Scottsdale, Arizona, United States
A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
- Conditions
- Interventions
- First Posted Date
- 2016-05-05
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 450
- Registration Number
- NCT02763319
- Locations
- 🇬🇧
MorphoSys Research Site, Southend on Sea, United Kingdom
🇬🇧Morphosys Research Site, Birmingham, United Kingdom
🇨🇿Morphosys Research site, Olomouc, Czechia
Open Label Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL
- Conditions
- Interventions
- First Posted Date
- 2015-03-26
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- MorphoSys AG
- Target Recruit Count
- 81
- Registration Number
- NCT02399085
- Locations
- 🇺🇸
CBCC Global Research, Inc. at Comprehensive Blood and Cancer Center, Bakersfield, California, United States
🇵🇱Szpital Wojewodzki Nr 1 im. Fryderyka Chopina w Rzeszowie, Rzeszow, Poland
🇺🇸Cancer Care - Torrance Memorial Physician Network, Redondo Beach, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.